

# USA HEALTH CLINICAL TRIALS ACTIVITY

10/1/2023 TO 9/30/2024

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
<b>UNIT: Mitchell Cancer Institute</b>							
<b>USA Health Clinical Trials</b>							
Abdalla,	Ahmed	NRG	NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ONEVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)	A23-0192-002	Continuation	9/2/2024	\$2,950
Abdalla,	Ahmed	NIH	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	A24-0047-001	New	1/25/2024	\$4,000
Abdalla,	Ahmed	NIH	A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED	A24-0052-001	New	1/3/2024	\$0
Abdalla,	Ahmed	NIH	PHASE II STUDY OF PACLITAXEL (NSC #673089) + IPATASERTIB (NSC #781451) IN TAXANE-REFRACTORY PARTICIPANTS WITH	A24-0072-001	New	3/5/2024	\$0
Abdalla,	Ahmed	NIH	A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS	A24-0118-001	New	5/16/2024	\$14,000
Abdalla,	Ahmed	ASTZ	A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for	A24-0133-001	New	6/4/2024	\$0
Alkharabsh	Omar	SGL	A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral	A20-0089-004	Continuation	9/2/2024	\$14,099
Alkharabsh	Omar	LOXOI	A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus	A22-0041-003	Continuation	9/2/2024	\$35,931
Alkharabsh	Omar	BMSI	A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing CC-92489 (BMS-986348), Carfilzomib, and Dexamethasone	A23-0085-002	Continuation	10/1/2023	\$253,567
Alkharabsh	Omar	LOXOI	A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax	A24-0035-001	New	12/19/2023	\$0
Alkharabsh	Omar	BGLTD	A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients	A24-0082-001	New	3/13/2024	\$0
Alkharabsh	Omar	MERCK	A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in	A24-0135-001	New	6/5/2024	\$0
Burch,	Kristie	VTECH	A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)	A24-0136-001	New	6/5/2024	\$0

# USA HEALTH CLINICAL TRIALS ACTIVITY

**10/1/2023 TO 9/30/2024**

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Dyess,	Donna	GNTC	B59	A 18-0198-007	Continuation	9/2/2024	\$7,440
Gremse,	David	QOL	Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase	A23-0213-001	New	5/2/2024	\$0
Gremse,	David	PHPHARM	A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and	A24-0104-001	New	4/8/2024	\$0
How ard,	John	NIH	A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-Risk Melanoma	A19-0252-005	Continuation	9/2/2024	\$0
How ard,	John	MERCK	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Follow ing	A21-0219-004	Continuation	9/2/2024	\$39,921
How ard,	John	CARIS	The Caris Biorepository Research Protocol	A21-0237-003	Continuation	9/2/2024	\$5,500
How ard,	John	NIH	S2015 Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide	A23-0095-003	Continuation	9/2/2024	\$72,900
Jones,	Nathaniel	MERCK	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without	A21-0119-004	Continuation	9/2/2024	\$29,345
Khushman,	Moh'D	NAT	BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer	A21-0065-004	Continuation	9/2/2024	\$16,112
Kilgo,	William		Clinical utility and decision impact of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis retrospective	A24-0230-001	New	9/30/2024	\$4,305
Naritoku,	Dean	XENON	A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as	A23-0210-001	New	3/5/2024	\$0
Naritoku,	Dean	XENON	A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy	A24-0083-001	New	3/13/2024	\$0
Pack-	Ardie		An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta (Voxelotor)	A23-0217-001	New	6/4/2024	\$0
Pai,	Sachin	MERCK	MCI Merck 5890-001 Ph 1 Solid Tumor	A20-0033-005	Continuation	9/2/2024	\$2,750

# USA HEALTH CLINICAL TRIALS ACTIVITY

**10/1/2023 TO 9/30/2024**

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Persing,	Brian	NIH	A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer	A21-0037-003	Continuation	9/2/2024	\$3,500
Persing,	Brian	MERCK	A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab	A21-0089-003	Continuation	9/2/2024	\$3,750
Persing,	Brian	NIH	PD-INHIBITOR (NIVOLUMAB) AND IPLIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III	A23-0202-001	New	12/1/2023	\$0
Pierce,	Jennifer	GOG	A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in	A24-0129-001	New	6/3/2024	\$0
Pierce,	Jennifer	GOG	A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in	A24-0129-002	Continuation	9/2/2024	\$43,500
Proddaturv	Pranitha	SIG	SGNTUC-016 HER2+	A20-0107-005	Continuation	9/2/2024	\$3,952
Proddaturv	Pranitha	BMSI	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant	A20-0124-005	Continuation	9/2/2024	\$21,034
Proddaturv	Pranitha	ASTZ	SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus	A21-0233-003	Continuation	9/2/2024	\$46,613
Proddaturv	Pranitha	ASTZ	DESTINY BREAST - RESPONDA multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second	A23-0207-001	New	1/25/2024	\$0
Proddaturv	Pranitha	GNTC	MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS	A23-0216-001	New	5/17/2024	\$0
Proddaturv	Pranitha	NIH	S2302, PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF	A24-0036-001	New	12/20/2023	\$10,000
Proddaturv	Pranitha	GNTC	RAMUCIRUMAB (LY3009806; NSC 749128) PLUS A PHASE I/III, MULTICENTER	A24-0119-001	New	5/16/2024	\$0
Proddaturv	Pranitha	GNTC	STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS	A24-0119-002	Continuation	9/2/2024	\$19,900
Proddaturv	Pranitha	AMGN	A PHASE I/III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS	A24-0132-001	New	6/4/2024	\$0
Proddaturv	Pranitha	AMGN	Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)	A24-0132-001	New	6/4/2024	\$0

## USA HEALTH CLINICAL TRIALS ACTIVITY

**10/1/2023 TO 9/30/2024**

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	FUNDING DATE	BUDGET AWARDS
Rocconi,	Rodney	UCHI	University of Chicago metformin advanced ovarian	A17-0205-004	Continuation	9/2/2024	\$28,000
Rocconi,	Rodney	CLSC	Celsion GEN 1 Ovarian	A18-0146-006	Continuation	9/2/2024	\$5,760
Rocconi,	Rodney	MERCK	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of	A20-0030-005	Continuation	9/2/2024	\$1,911
Scalici,	Jennifer	GOG	Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer	A21-0117-003	Continuation	9/2/2024	\$7,042
Scalici,	Jennifer	GOG	A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH	A23-0061-002	Continuation	9/2/2024	\$24,421
Scalici,	Jennifer	GENE	A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and	A23-0109-002	Continuation	9/2/2024	\$33,000
Scalici,	Jennifer	KGB	A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian	A23-0174-002	Continuation	9/2/2024	\$27,650
Scalici,	Jennifer	IMMG	Randomized, multicenter, open-label, Phase 3 study of mirvetuximabsoravtansine in combination with bevacizumab versus	A23-0196-001	New	10/30/2023	\$0
Scalici,	Jennifer	IMMG	Randomized, multicenter, open-label, Phase 3 study of mirvetuximabsoravtansine in combination with bevacizumab versus	A23-0196-002	Continuation	9/2/2024	\$47,978
Scalici,	Jennifer	NIH	MOLECULAR ANALYSIS FOR COMBINATION THERAPY CHOICE (ComboMATCH) EAY191-N4: A RANDOMIZED TRIAL OF SELUMETINIB AND	A24-0105-001	New	4/9/2024	\$3,600
Scalici,	Jennifer	GOG	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus	A24-0117-001	New	5/15/2024	\$38,000
<b>TOTAL FOR DEPARTMENT: USA Health Clinical Trials</b>							<b>\$872,431</b>